result from a weakened area in an artery of the brain that fills with blood and causes outward bulging or ballooning.

The Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial () focuses on the safety and effectiveness of the SEAL system, which can be used to treat patients with ruptured and unruptured brain aneurysms in a range of sizes.

“I’m excited to be a part of groundbreaking aneurysm treatment research, and for the opportunity to bring patients in Louisville and the surrounding region a novel treatment option not yet widely available,” said  a neurosurgeon with Brain & Spine Institute and assistant professor in the UofL Department of Neurological Surgery. “The device is small enough that we can use a minimally invasive technique via an artery in the groin to deliver the device and disrupt the blood flow to the aneurysm, causing it to clot and heal, while decreasing the need for more invasive procedures like a craniotomy.”

Patients with brain aneurysms are usually asymptomatic until their aneurysm ruptures. A ruptured aneurysm is a form of stroke and a potentially life-threatening condition that can result in brain damage or death.

“As an academic health care system affiliated with the University of Louisville, we are committed to providing our patients with the latest innovative treatments, including those offered through clinical trials,” said Joshua Beardsley, system vice president of neurosciences and spine. “I’m proud of our providers for helping to pioneer the next generation of aneurysm care.”

About SEAL IT

SEAL IT is a prospective, U.S. and international single-arm, multicenter, interventional study. The clinical trial seeks to establish the safety and effectiveness of the system in treating patients with wide neck unruptured or ruptured intracranial aneurysms that are less than or equal to 19 millimeters in widest diameter. Data such as imaging and patient presentation will be collected from participants immediately after their procedure in addition to three, six and 12 months after their procedure. Participants will receive follow-ups annually for five years.

Autism is a spectrum of developmental disabilities impacting social skills, language processing, cognition and other functions. The UofL tool has been shown to be 98.5% accurate in diagnosing kids as young as two, which could give doctors more time to intervene with potentially life-changing therapy. Their results were published in the journal .

“Therapy could be the difference between an individual needing full-time care and being independent, holding a job and living a fulfilled life,” said Ayman El-Baz, a co-inventor and professor and chair in the . He developed the technology with Gregory Barnes and Manuel Casanova of the UofL .

shows therapy can have the most impact if done in early childhood, when the brain is more elastic. However, currently, and even fewer are diagnosed by age eight. The problem, the researchers say, is one of supply and demand — there are too many patients and too few specialists to conduct the interviews and examinations needed for diagnosis.

“As a result, there’s an urgent need for a new, objective technology that can help us diagnose kids early,” said Barnes, a professor of neurology and executive director of the . “We think our tool can help fill that need, while providing more objectivity over the current interview method.”

With the UofL technology, AI can make the initial diagnosis, which researchers think could reduce specialist workload by as much as 30%. The specialist would meet later with the patient to confirm the diagnosis and talk about next steps.

The UofL technology works by using AI to analyze magnetic resonance imaging (MRI) scans for differences and abnormal connections that may indicate autism. Tested against scans of 226 children between the ages of 24 and 48 months, the technology was able to identify the 120-some children with autism with near perfect accuracy.

By looking at the physical structures of the brain rather than using interviews, researchers believe they can make diagnoses more objective and target the specific parts of the brain that may benefit most from therapy.

“The idea is that by drawing from both medicine and engineering, we can come up with a better solution that improves lives,” said Mohamed Khudri, a undergraduate student and author on the paper.

The diagnostic technology and intellectual property received support through . That includes the office’s suite of innovation programs, aimed at developing research-backed inventions for market, including the prestigious national Innovation Corps (I-Corps) program through the National Science Foundation. UofL is one of only a handful of universities nationwide to have each of these programs — and it’s the only one to have them all.